Use of Paricalcitol & Cinacalcet in Patients with Kidney Failure

Use of Paricalcitol & Cinacalcet in Patients with Kidney Failure

CheshireandMerseyside KidneyCareNetwork UseofParicalcitol&CinacalcetinPatientswithKidney Failure IthasbeenagreedandratifiedbytheKidneyCareNetworkthattheuseofParicalcitolcan beconsideredinthefollowingpatientsituations: 1.DialysispatientsintoleranttoCinacalcet. Cinacalcetcanbeconsideredindialysispatientsinthefollowingsituation: i) Parathyroidlevelsconsistently6ormoretimestheupperlimitofnormalon2 consecutivereadingsovertheprevious3months; ii) Adjustedserumcalciumlevels>2.7mmol/Loveraperiodof3months;thepatient mustnotbetakingcalciumcontainingphosphatebindersorcalciumsupplements andmustbeonalowcalciumdialysateof1.25mmol/Lorless; iii) PatientprescribedmaximaldoseofpulsedAlfacalcidolorCalcitriolforatleast3 monthswithnoreductioninPTHorexperiencingdose-limitinghypercalcaemia; iv) Patientunwillingorunsuitableforparathyroidectomy. 2.Dialysispatientswithadjustedserumcalciumlevels>2.7mmol/Landparathyroid levels 2 – 6 times upper limit of normal over a 3-month period (not indicative for Cinacalcet), despite stopping calcium containing binders and using pulsed AlfacalcidolorCalcitriol ; oralorintravenousParicalcitolmaybeprescribedatainitial doseof2mcgtwiceaweekbytherenalconsultants. Serumcalciumshouldbemonitoredweeklyduringinitiationandafteradosechange,then monthlyonceastablemaintenancedoseisreached.Parathyroidhormonelevelstobe monitored4weeklyduringinitiationanddosemaybeincreasedtomaximumof2mcgthrice weeklyifPTHremainsaboverecommendedrangeorreducedto1mcgtwiceweeklyincase ofpersistenthypercalcaemia.Onceastablemaintenancedoseisreached,serumcalcium willbemonitoredmonthlyandPTH3monthly. IfpatientremainshypercalcaemicontheminimaldoseofParicalcitolrequiredtocontrolPTH levelorifPTHremainsaboverecommendedtargetdespitethemaximalallowabledoseof Paricalcitolforatleastthreemonths,thentherapyshouldbewithdrawn. PatientsprescribedParicalcitolshouldstoptakingAlfacalcidolorCalcitriol. Consideri/vParicalcitolifpatientnon-concordantwithmedications. DateApproved: July2009 DateforReview: January2011 UseofParicalcitrol&CinacalcetinPatientswithKidneyFailure July2009 Page1of1.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    1 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us